Author: Lucy J. Sannes, PhD, MBA
CHAPTER 1: INTRODUCTION
1.1. The Immune System
1.2. Scope of the Report
CHAPTER 2: REVIEW OF MAJOR DISEASES/ CONDITIONS TARGETED BY NEW AND/OR EMERGING IMMUNOTHERAPIES AND VACCINES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM
2.1. Major Autoimmune Diseases
Rheumatoid Arthritis
Type 1 Diabetes Mellitus
Inflammatory Bowel Disease—Crohn’s
Disease and Ulcerative Colitis
Multiple Sclerosis
Psoriasis
Psoriatic Arthritis
Systemic Lupus Erythematosus
2.2. Asthma
2.3. Allergies
2.4. Immune Suppression to Prevent
Rejection of Organ Transplants
CHAPTER 3: CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
3.1. Major Autoimmune Diseases
Rheumatoid Arthritis
Nonsteroidal Anti-inflammatory Drugs
(NSAIDs)
Disease-Modifying Antirheumatic
Drugs (DMARDs)
Corticosteroids
Biological Response Modifiers
Type 1 Diabetes Mellitus
Inflammatory Bowel Disease—Crohn’s
Disease and Ulcerative Colitis
Multiple Sclerosis
Interferon-beta
Copaxone (glatiramer acetate)
Novantrone (mitoxantrone)
Tysabri (natalizumab)
Psoriasis
Psoriatic Arthritis
Systemic Lupus Erythematosus
3.2. Asthma
3.3. Allergies
3.4. Immune Suppression to Prevent Rejection of Organ Transplants
CHAPTER 4: CURRENT AND EMERGING APPROACHES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE
CHAPTER 5: EMERGING THERAPIES IN DEVELOPMENT FOR TREATMENT OF MAJOR AUTOIMMUNE DISEASES
5.1. Introduction
5.2. Abbott Laboratories
5.3. Biogen Idec
5.4. AstraZeneca
5.5. Bristol-Myers Squibb
5.6. Centocor Ortho Biotech
5.7. Centocor Ortho Biotech and Schering-Plough
5.8. Diamyd Medical
5.9. Eli Lilly and BioMS Medical
5.10. Eli Lilly and MacroGenics
5.11. Genzyme and Bayer
5.12. GlaxoSmithKline and Genmab
5.13. GlaxoSmithKline and Human Genome Sciences
5.14. GlaxoSmithKline and Tolerx
5.15. GlaxoSmithKline (Selected Additional Product Candidates and Research)
5.16. Isotechnika
5.17. Merck Serono and ZymoGenetics
5.18. Merck Serono
5.19. Novartis
Multiple Sclerosis
Rheumatoid Arthritis
Psoriasis
5.20. Pfizer
5.21. Roche and Chugai Pharmaceutical
5.22. Roche and Genentech (A Wholly-Owned Member of the Roche Group)
5.23. Sanofi-Aventis
5.24. Takeda Pharmaceutical and Millennium Pharmaceuticals
5.25. Teva Pharmaceutical Industries and Active Biotech
5.26. UCB
CHAPTER 6: EMERGING THERAPIES FOR TREATMENT OF ASTHMA
6.1. Pipeline Overview
6.2. Abbott Laboratories and SkyePharma (Also Mundipharma and Kyorin)
6.3. Aerovance
6.4. Amgen
6.5. AstraZeneca
6.6. Ception Therapeutics
6.7. Genentech
6.8. GlaxoSmithKline
6.9. Icagen
6.10. MediciNova
6.11. Pfizer
6.12. Schering-Plough and Novartis
6.13. Topigen Pharmaceuticals
6.14. Wyeth
CHAPTER 7: SELECTED EXAMPLES OF EMERGING THERAPIES FOR TREATMENT OF ALLERGIES
7.1. Introduction
7.2. ALK-Abello and Schering-Plough
7.3. Allergy Therapeutics
7.4. Ception Therapeutics
7.5. Cytos Biotechnology
7.6. Greer Laboratories
7.7. Stallergenes
CHAPTER 8: IMMUNOTHERAPIES IN DEVELOPMENT FOR PREVENTING REJECTION OF ORGAN TRANSPLANTS
8.1. Introduction
8.2. APT Pharmaceuticals
8.3. Astellas Pharma
8.4. Bristol-Myers Squibb
8.5. Isotechnika
8.6. Novartis
8.7. Pfizer
CHAPTER 9: BUSINESS CONSIDERATIONS —THERAPIES THAT SUPPRESS OR BALANCE THE IMMUNE SYSTEM
9.1. Current Market and Market Potential
9.2. Competition
9.3. Strong Interest on the Part of Major Pharmaceutical Companies
9.4. Agreements and Mergers/Acquisitions
9.5. Other Major Challenges and Hurdles Being Faced by Companies
Competition
Potential Need for Personalized Medicine in at Least Certain Situations
Targeted Patient Populations
CHAPTER 10: THOUGHT LEADER INTERVIEWS
10.1. David W. Pritchard, President and Chief Executive Officer, KaloBios
10.2. Randall C. Schatzman, PhD, President and Chief Executive Officer, Alder
Biopharmaceuticals
10.3. Louis Vaickus, MD, Chief Medical
Officer, Tolerx
10.4. Eric H. Zanelli, PhD, Vice President, Research, Peptimmune
REFERENCES
COMPANY INDEX WITH WEB ADDRESSES